Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry.
Giuseppe BorianiRaffaele De CaterinaMarius Constantin ManuJosé SouzaLadislav PecenPaulus F KirchhofPublished in: Journal of clinical medicine (2021)
Low rates of stroke and bleeding were reported with edoxaban, independent of weight. The risk of all-cause death was higher in extremes of weight vs. the reference group after adjustment for important risk modifiers, thus no obesity paradox was observed.
Keyphrases
- atrial fibrillation
- weight loss
- weight gain
- body mass index
- end stage renal disease
- physical activity
- left atrial
- catheter ablation
- oral anticoagulants
- venous thromboembolism
- ejection fraction
- left atrial appendage
- newly diagnosed
- metabolic syndrome
- chronic kidney disease
- body weight
- type diabetes
- direct oral anticoagulants
- heart failure
- peritoneal dialysis
- prognostic factors
- adipose tissue
- high fat diet induced
- subarachnoid hemorrhage
- coronary artery disease
- mitral valve
- left ventricular
- replacement therapy